GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

The US Food and Drug Administration (FDA) has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs ...

For patients with unresectable, nonmetastatic hepatocellular carcinoma, transarterial chemoembolization (TACE) with the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

IT WAS A freezing winter’s day in London as patrons jostled in a poky outpost of Blank Street, a coffee-shop chain. You might ...

The FDA has accepted the BLA for lecanemab-irmb SC for weekly maintenance dosing in the treatment of early Alzheimer disease.

The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...